In 1993, an International Task Force for Disease Eradication evaluated over 80 potential candidate diseases and made recommendations. However, little has been done to develop the science of eradication systematically. This book reports the findings of a multidisciplinary workshop on the eradication of infectious diseases. It reviews the history of eradication efforts and lessons from previous campaigns and distinguishes among eradication, elimination, and control programs and extinction of an etiologic agent. It addresses a wide range of related issues, including biological and socio-political criteria for eradication, costs and benefits of eradication campaigns, opportunities for strengthening primary health care in the course of eradication efforts, and other aspects of planning and implementing eradication programs. Finally, it stresses the importance of global mechanisms for formulating and implementing such programs.

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

The World Health Organization's Global Technical Strategy for Malaria 2016- 2030 has been developed with the aim to help countries to reduce the human suffering caused by the world's deadliest mosquito-borne disease. Adopted by the World Health Assembly in May 2015 it provides comprehensive technical guidance to countries and development partners for the next 15 years emphasizing the importance of scaling up malaria responses and moving towards elimination. It also highlights the urgent need to increase investments across all interventions - including preventive measures diagnostic testing treatment and disease surveillance- as well as in harnessing innovation and expanding research. By adopting this strategy WHO Member States have endorsed the bold vision of a world free of malaria and set the ambitious new target of reducing the global malaria burden by 90% by 2030. They also agreed to strengthen health systems address emerging multi-drug and insecticide resistance and intensify national cross-border and regional efforts to scale up malaria responses to protect everyone at risk.

This title examines the international lawfulness of state-sponsored targeted killings in military and police operations. Analysing recent state practice and jurisprudence, it establishes when targeted killing may be considered lawful, and what legal restraints are imposed on the practice in times of war and peace.

Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.

NEW YORK TIMES BESTSELLER • The first definitive history of the Mossad, Shin Bet, and the IDF’s targeted killing programs, hailed by The New York Times as “an exceptional work, a humane book about an incendiary subject.” WINNER OF THE NATIONAL JEWISH BOOK AWARD IN HISTORY NAMED ONE OF THE TEN BEST BOOKS OF THE YEAR BY JENNIFER SZALAI, THE NEW YORK TIMES NAMED ONE OF THE BEST BOOKS OF THE YEAR BY The Economist • The New York Times Book Review • BBC History Magazine • Mother Jones • Kirkus Reviews The Talmud says: “If someone comes to kill you, rise up and kill him first.” This instinct to take every measure, even the most aggressive, to defend the Jewish people is hardwired into Israel’s DNA. From the very beginning of its statehood in 1948, protecting the nation from harm has been the responsibility of its intelligence community and armed services, and there is one weapon in their vast arsenal that they have relied upon to thwart the most serious threats: Targeted assassinations have been used countless times, on enemies large and small, sometimes in response to attacks against the Israeli people and sometimes preemptively. In this page-turning, eye-opening book, journalist and military analyst Ronen Bergman—praised by David Remnick as “arguably [Israel’s] best investigative reporter”—offers a riveting inside account of the targeted killing programs: their successes, their failures, and the moral and political price exacted on the men and women who approved and carried out the missions. Bergman has gained the exceedingly rare cooperation of many current and former members of the Israeli government, including Prime Ministers Shimon Peres, Ehud Barak, Ariel Sharon, and Benjamin Netanyahu, as well as high-level figures in the country’s military and intelligence services: the IDF (Israel Defense Forces), the Mossad (the world’s most feared intelligence agency), Caesarea (a “Mossad within the Mossad” that carries out attacks on the highest-value targets), and the Shin Bet (an internal security service that implemented the largest targeted assassination campaign ever, in order to stop what had once appeared to be unstoppable: suicide terrorism). Including never-before-reported, behind-the-curtain accounts of key operations, and based on hundreds of on-the-record interviews and thousands of files to which Bergman has gotten exclusive access over his decades of reporting, Rise and Kill First brings us deep into the heart of Israel’s most secret activities. Bergman traces, from statehood to the present, the gripping events and thorny ethical questions underlying Israel’s targeted killing campaign, which has shaped the Israeli nation, the Middle East, and the entire world. “A remarkable feat of fearless and responsible reporting . . . important, timely, and informative.”—John le Carré

There have been calls to revisit the experiences of TB screening campaigns that were widely applied in Europe and North America in the mid-20th century, as well as more recent experiences with TB screening in countries with a high burden of the disease, and to assess their possible relevance for TB care and prevention in the 21st century. In response, WHO has developed guidelines on screening for active TB. An extensive review of the evidence has been undertaken. The review suggests that screening, if done in the right way and targeting the right people, may reduce suffering and death, but the review also highlights several reasons to be cautious. As discussed in detail in this book, there is a need to balance potential benefits against the risks and costs of screening; this conclusion is mirrored by the history of TB screening. This publication presents the first comprehensive assessment by WHO of the appropriateness of screening for active TB since the recommendations made in 1974 by the Expert Committee. However, the relative effectiveness and cost effectiveness of screening remain uncertain, a point that is underscored by the systematic reviews presented in this guideline. Evidence suggests that some risk groups should always be screened, whereas the prioritization of other risk groups as well as the choice of screening approach depend on the epidemiology, the health-system context, and the resources available. This book sets out basic principles for prioritizing risk groups and choosing a screening approach; it also emphasizes the importance of assessing the epidemiological situation, adapting approaches to local situations, integrating TB screening into other health-promotion activities, minimizing the risk of harm to individuals, and engaging in continual monitoring and evaluation. It calls for more and better research to assess the impact of screening and to develop and evaluate new screening tests and approaches.

Why do diseases of poverty afflict more people in wealthy countries than in the developing world? In 2011, Dr. Peter J. Hotez relocated to Houston to launch Baylor’s National School of Tropical Medicine. He was shocked to discover that a number of neglected diseases often associated with developing countries were widespread in impoverished Texas communities. Despite the United States’ economic prowess and first-world status, an estimated 12 million Americans living at the poverty level currently suffer from at least one neglected tropical disease, or NTD. Hotez concluded that the world’s neglected diseases—which include tuberculosis, hookworm infection, lymphatic filariasis, Chagas disease, and leishmaniasis—are born first and foremost of extreme poverty. In this book, Hotez describes a new global paradigm known as “blue marble health,” through which he asserts that poor people living in wealthy countries account for most of the world’s poverty-related illness. He explores the current state of neglected diseases in such disparate countries as Mexico, South Korea, Argentina, Australia, the United States, Japan, and Nigeria. By crafting public policy and relying on global partnerships to control or eliminate some of the world’s worst poverty-related illnesses, Hotez believes, it is possible to eliminate life-threatening disease while at the same time creating unprecedented opportunities for science and diplomacy. Clear, compassionate, and timely, Blue Marble Health is a must-read for leaders in global health, tropical medicine, and international development, along with anyone committed to helping the millions of people who are caught in the desperate cycle of poverty and disease.

Towards Malaria Elimination - A Leap Forward was started to mark the occasion for renewed commitment to end malaria transmission for good (the WHO's call for "Malaria Free World" by 2030). This book is dedicated for the benefit of researchers, scientists, program and policy managers, students and anyone interested in malaria and other mosquito-borne diseases with the goal of sharing recent information on success stories, innovative control approaches and challenges in different regions of the world. Some main issues that emerged included multidrug-resistant malaria and pandemic risk, vaccines, cross-border malaria, asymptomatic parasite reservoir, the threat of Plasmodium vivax and Plasmodium knowlesi, insecticide resistance in Anopheles vectors and outdoor malaria transmission. This book is one little step forward to bring together in 17 chapters the experiences of malaria-expert researchers from five continents to present updated information on disease epidemiology and control at the national/regional level, highlighting the constraints, challenges, accomplishments and prospects of malaria elimination.